SEC Form 4 · accession 0001628280-26-058648
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 24, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2026 | M | 1,072 | $7.51 | A | 24,598 | D | |
| Common StockF2 | Aug 20, 2026 | S | 1,072 | $26.0376 | D | 23,526 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.51 | Aug 20, 2026 | M | 1,072 | D | — | May 31, 2033 | Common Stock | 1,072 | 11,148 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The option is fully vested.